Eton Pharmaceuticals, INC 10-Q quarterly reports

Eton Pharmaceuticals, Inc. announced its first quarter 2026 financial results, showing a significant increase in net revenues and a return to profitability.

Eton Pharmaceuticals, Inc. reported significant revenue growth and a substantial increase in cash from operating activities for the nine months ended September 30, 2025, driven by new product sales and licensing deals, despite a larger net loss.

Eton Pharmaceuticals reported a significant increase in total net revenues and gross profit for the first half of 2025, driven by new product acquisitions and licensing deals, alongside a positive shift in cash flow from operations.

Eton Pharmaceuticals saw a significant increase in total revenue and gross profit for the first quarter of 2025, driven by product sales and licensing agreements.

Eton Pharmaceuticals saw revenue growth in Q3 2024, primarily driven by increased product sales and royalties, alongside the launch of new products.

Eton Pharmaceuticals' second quarter 2024 results show a decrease in total revenue compared to the same period last year, primarily due to a prior sale of royalty interests, though product sales have increased.

Eton Pharmaceuticals saw a revenue increase in the first quarter of 2024, primarily driven by higher sales of ALKINDI SPRINKLE and Carglumic Acid.